CA3139277A1 - Jak inhibitors - Google Patents
Jak inhibitors Download PDFInfo
- Publication number
- CA3139277A1 CA3139277A1 CA3139277A CA3139277A CA3139277A1 CA 3139277 A1 CA3139277 A1 CA 3139277A1 CA 3139277 A CA3139277 A CA 3139277A CA 3139277 A CA3139277 A CA 3139277A CA 3139277 A1 CA3139277 A1 CA 3139277A1
- Authority
- CA
- Canada
- Prior art keywords
- c6alkyl
- solvate
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845119P | 2019-05-08 | 2019-05-08 | |
| US62/845,119 | 2019-05-08 | ||
| US201962884588P | 2019-08-08 | 2019-08-08 | |
| US62/884,588 | 2019-08-08 | ||
| PCT/US2020/031925 WO2020227563A1 (en) | 2019-05-08 | 2020-05-07 | Jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3139277A1 true CA3139277A1 (en) | 2020-11-12 |
Family
ID=73051620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3139277A Pending CA3139277A1 (en) | 2019-05-08 | 2020-05-07 | Jak inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11136329B2 (enExample) |
| EP (1) | EP3966209A4 (enExample) |
| JP (1) | JP7617030B2 (enExample) |
| KR (1) | KR102916168B1 (enExample) |
| CN (1) | CN114269734B (enExample) |
| AU (1) | AU2020267661B2 (enExample) |
| BR (1) | BR112021022380A2 (enExample) |
| CA (1) | CA3139277A1 (enExample) |
| IL (1) | IL287876A (enExample) |
| MX (1) | MX2021013602A (enExample) |
| SG (1) | SG11202112362YA (enExample) |
| TW (1) | TWI865525B (enExample) |
| WO (1) | WO2020227563A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114269734B (zh) | 2019-05-08 | 2026-03-27 | 维玛兰生物科学公司 | Jak抑制剂 |
| CA3150281A1 (en) | 2019-08-08 | 2021-02-11 | Vimalan Biosciences, Inc. | Jak inhibitors |
| CN114644633B (zh) * | 2020-12-18 | 2026-02-03 | 北京诺诚健华医药科技有限公司 | 杂环类jak抑制剂 |
| KR102637915B1 (ko) * | 2021-06-25 | 2024-02-19 | 한국화학연구원 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101801971A (zh) | 2005-09-30 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作janus激酶抑制剂的脱氮嘌呤 |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| AU2008211172A1 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | 1-H-pyrazolo(3,4B)pyrimidine derivatives and their use as modulators of mitotic kinases |
| UY31631A1 (es) | 2008-02-06 | 2009-09-30 | Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones | |
| AU2009284098B2 (en) * | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| EA022120B1 (ru) * | 2009-10-20 | 2015-11-30 | Целльзом Лимитид | Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak |
| WO2011134831A1 (en) | 2010-04-30 | 2011-11-03 | Cellzome Limited | Pyrazole compounds as jak inhibitors |
| WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| WO2012143320A1 (en) * | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
| KR20140063700A (ko) * | 2011-09-20 | 2014-05-27 | 셀좀 리미티드 | 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체 |
| EA025186B1 (ru) | 2012-06-29 | 2016-11-30 | Пфайзер Инк. | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 |
| BR112017027951A2 (pt) | 2015-06-22 | 2018-08-28 | Ono Pharmaceutical Co., Ltd. | composto inibitório de brk |
| CN108864057B (zh) * | 2017-05-16 | 2020-03-31 | 山东大学 | 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用 |
| CN114269734B (zh) | 2019-05-08 | 2026-03-27 | 维玛兰生物科学公司 | Jak抑制剂 |
| CA3150281A1 (en) | 2019-08-08 | 2021-02-11 | Vimalan Biosciences, Inc. | Jak inhibitors |
| EP4034107A4 (en) | 2019-09-25 | 2023-08-30 | Vimalan Biosciences, Inc. | JAK INHIBITORS |
-
2020
- 2020-05-07 CN CN202080050268.XA patent/CN114269734B/zh active Active
- 2020-05-07 AU AU2020267661A patent/AU2020267661B2/en active Active
- 2020-05-07 MX MX2021013602A patent/MX2021013602A/es unknown
- 2020-05-07 US US16/869,433 patent/US11136329B2/en active Active
- 2020-05-07 BR BR112021022380A patent/BR112021022380A2/pt unknown
- 2020-05-07 CA CA3139277A patent/CA3139277A1/en active Pending
- 2020-05-07 JP JP2021566284A patent/JP7617030B2/ja active Active
- 2020-05-07 KR KR1020217040186A patent/KR102916168B1/ko active Active
- 2020-05-07 EP EP20801611.3A patent/EP3966209A4/en active Pending
- 2020-05-07 WO PCT/US2020/031925 patent/WO2020227563A1/en not_active Ceased
- 2020-05-07 SG SG11202112362YA patent/SG11202112362YA/en unknown
- 2020-05-08 TW TW109115406A patent/TWI865525B/zh active
-
2021
- 2021-11-07 IL IL287876A patent/IL287876A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021022380A2 (pt) | 2022-03-22 |
| MX2021013602A (es) | 2022-04-06 |
| AU2020267661B2 (en) | 2026-05-07 |
| US20200369669A1 (en) | 2020-11-26 |
| EP3966209A1 (en) | 2022-03-16 |
| JP2022532877A (ja) | 2022-07-20 |
| WO2020227563A1 (en) | 2020-11-12 |
| AU2020267661A1 (en) | 2021-12-23 |
| TW202108587A (zh) | 2021-03-01 |
| TWI865525B (zh) | 2024-12-11 |
| CN114269734A (zh) | 2022-04-01 |
| EP3966209A4 (en) | 2023-01-04 |
| CN114269734B (zh) | 2026-03-27 |
| IL287876A (en) | 2022-01-01 |
| US11136329B2 (en) | 2021-10-05 |
| KR20220052859A (ko) | 2022-04-28 |
| SG11202112362YA (en) | 2021-12-30 |
| JP7617030B2 (ja) | 2025-01-17 |
| KR102916168B1 (ko) | 2026-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020267661B2 (en) | JAK inhibitors | |
| JP7635228B2 (ja) | Ｔｙｋ２偽キナーゼリガンド | |
| US11780842B2 (en) | TYK2 pseudokinase ligands | |
| CA3129438A1 (en) | Tyk2 pseudokinase ligands | |
| EP4034107A1 (en) | Jak inhibitors | |
| CA3150281A1 (en) | Jak inhibitors | |
| HK40072097A (en) | Jak inhibitors | |
| HK40080028A (en) | Tyk2 pseudokinase ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240503 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250502 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250502 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250605 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250923 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251126 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251126 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20260429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260501 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260506 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260512 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260512 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260512 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260617 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260617 |